Is cartilage matrix breakdown an appropriate therapeutic target in osteoarthritis--insights from studies of aggrecan and collagen proteolysis?
Progressive cartilage degradation is considered a hallmark of osteoarthritis (OA), and as such methods to inhibit this process have been extensively investigated as potential disease-modifying therapies. However, all tissues of the joint are affected by disease in OA, and it is likely that the pain...
Saved in:
Published in | Current drug targets Vol. 11; no. 5; p. 561 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United Arab Emirates
01.05.2010
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Progressive cartilage degradation is considered a hallmark of osteoarthritis (OA), and as such methods to inhibit this process have been extensively investigated as potential disease-modifying therapies. However, all tissues of the joint are affected by disease in OA, and it is likely that the pain and disability which are the major clinical symptoms of OA, arise predominantly from pathology in these extra-cartilaginous structures. It is unclear therefore, whether specifically targeting inhibition of cartilage matrix breakdown will ameliorate global joint pathology and thereby affect the clinically-relevant OA-related disability. We have investigated this question by reviewing the literature and data available from studies of genetically-modified (GM) mice. A total of 79 different GM strains were identified in which OA-like cartilage erosion was analysed, 53 with increased, 18 with no change, and 8 with decreased cartilage damage. Inhibition of OA cartilage damage was afforded by mutations that either reduced chondrocyte hypertrophy or abrogated proteolysis of aggrecan and collagen II in cartilage. There was an association between increased cartilage breakdown and changes in subchondral bone, osteophytosis and synovial hyperplasia in GM mice. However, the effect of significantly inhibiting cartilage damage on pathology in other joints tissues has been less well examined. There appeared to be no diminution of osteophyte development in chondroprotected GM mice strains, but a possible reduction in subchondral bone plate changes. To date, there is no conclusive data on the effect of inhibiting cartilage breakdown on clinical signs of OA in GM mice. These studies have highlighted the tremendous advances studies of GM mice have afforded us in understanding the pathophysiology of cartilage degradation in OA. Furthermore they demonstrate the feasibility of targeting cartilage matrix destruction. However, it is evident that an important direction for ongoing research will be to determine the effect of successful protection of cartilage structural integrity on pathology in other tissues in the OA joint, and the clinical signs of the disease. |
---|---|
AbstractList | Progressive cartilage degradation is considered a hallmark of osteoarthritis (OA), and as such methods to inhibit this process have been extensively investigated as potential disease-modifying therapies. However, all tissues of the joint are affected by disease in OA, and it is likely that the pain and disability which are the major clinical symptoms of OA, arise predominantly from pathology in these extra-cartilaginous structures. It is unclear therefore, whether specifically targeting inhibition of cartilage matrix breakdown will ameliorate global joint pathology and thereby affect the clinically-relevant OA-related disability. We have investigated this question by reviewing the literature and data available from studies of genetically-modified (GM) mice. A total of 79 different GM strains were identified in which OA-like cartilage erosion was analysed, 53 with increased, 18 with no change, and 8 with decreased cartilage damage. Inhibition of OA cartilage damage was afforded by mutations that either reduced chondrocyte hypertrophy or abrogated proteolysis of aggrecan and collagen II in cartilage. There was an association between increased cartilage breakdown and changes in subchondral bone, osteophytosis and synovial hyperplasia in GM mice. However, the effect of significantly inhibiting cartilage damage on pathology in other joints tissues has been less well examined. There appeared to be no diminution of osteophyte development in chondroprotected GM mice strains, but a possible reduction in subchondral bone plate changes. To date, there is no conclusive data on the effect of inhibiting cartilage breakdown on clinical signs of OA in GM mice. These studies have highlighted the tremendous advances studies of GM mice have afforded us in understanding the pathophysiology of cartilage degradation in OA. Furthermore they demonstrate the feasibility of targeting cartilage matrix destruction. However, it is evident that an important direction for ongoing research will be to determine the effect of successful protection of cartilage structural integrity on pathology in other tissues in the OA joint, and the clinical signs of the disease. |
Author | Fosang, Amanda J Little, Christopher B |
Author_xml | – sequence: 1 givenname: Christopher B surname: Little fullname: Little, Christopher B email: christopher.little@sydney.edu.au organization: Raymond Purves Bone and Joint Research Labs, Kolling Institute of Medical Research, Institute of Bone & Joint Research, University of Sydney, Level 10 Kolling Building-B6, Royal North Shore Hospital, St Leonards, NSW 2062, Australia. christopher.little@sydney.edu.au – sequence: 2 givenname: Amanda J surname: Fosang fullname: Fosang, Amanda J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20199393$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kNtKxDAYhIMoHlZfwAvJC1RzaNrmSmTxsLDgjV4vf5M_3WDblCSL7kv4zHZRYWCu5htmLsjxGEYk5JqzW8Hr8o7LRpeKcVZrzjjXqjoi57ypZaGUFqfkTDCutdTynHyvEjUQs--hQzpAjv6LthHhw4bPkcKsaYphih4y0rzFCBPusjc0Q-wwUz_SkDKGmbGNPvtUFH5MvtvmRF0MA015Zz0mGhyFrotoDszRUhP6Q-dIZ_yc7_fJp_tLcuKgT3j15wvy_vT4tnwp1q_Pq-XDumhLLXJRYdUo62RpHWfCGUBQ2nLVKoaOVwwYE6VkpZPYADjDUDQttNCwWpWmkmJBbn65064d0G7mfQPE_eb_GPEDrnpnZA |
CitedBy_id | crossref_primary_10_1007_s11420_011_9250_z crossref_primary_10_1016_j_bbapap_2011_06_020 crossref_primary_10_1002_art_34574 crossref_primary_10_1007_s11926_015_0524_1 crossref_primary_10_1016_j_joca_2012_01_017 crossref_primary_10_1111_iep_12230 crossref_primary_10_1177_1947603515586048 crossref_primary_10_15406_mojor_2018_10_00437 crossref_primary_10_1590_1678_4685_gmb_2019_0115 crossref_primary_10_1002_term_2916 crossref_primary_10_1039_C9FO01342C crossref_primary_10_1088_0031_9155_57_24_8173 crossref_primary_10_1007_s11095_012_0870_x crossref_primary_10_1038_nrrheum_2013_72 crossref_primary_10_1002_art_37970 crossref_primary_10_1093_rheumatology_kex399 crossref_primary_10_3390_ijms23116003 crossref_primary_10_3109_1354750X_2015_1130190 crossref_primary_10_1016_j_heliyon_2024_e31028 crossref_primary_10_1089_ten_tea_2014_0668 crossref_primary_10_2147_JPR_S244372 crossref_primary_10_1177_1947603517720260 crossref_primary_10_1177_1947603518809401 crossref_primary_10_1142_S0192415X13500948 crossref_primary_10_1016_j_joca_2024_06_016 crossref_primary_10_1038_s41598_018_25186_1 crossref_primary_10_1016_j_joca_2015_09_005 crossref_primary_10_1007_s11926_013_0350_2 crossref_primary_10_1016_j_cger_2021_11_015 crossref_primary_10_1155_2016_6432867 crossref_primary_10_1016_j_joca_2021_03_024 crossref_primary_10_1080_03008207_2016_1177036 crossref_primary_10_1002_jor_23343 crossref_primary_10_1016_j_bone_2011_10_008 crossref_primary_10_1155_2011_683970 crossref_primary_10_3892_ijmm_2015_2446 crossref_primary_10_1016_j_joca_2013_02_004 crossref_primary_10_1186_s13018_019_1160_7 crossref_primary_10_1016_j_jmbbm_2014_06_008 crossref_primary_10_1007_s00296_018_4103_4 crossref_primary_10_1038_mtna_2016_64 crossref_primary_10_1115_1_4064663 crossref_primary_10_1016_j_joca_2021_08_012 crossref_primary_10_1080_03008207_2017_1284824 crossref_primary_10_1021_acs_jproteome_5b01115 crossref_primary_10_1371_journal_pone_0092699 crossref_primary_10_1177_1759720X12448454 crossref_primary_10_1016_j_molmed_2011_11_005 crossref_primary_10_1101_gad_1939310 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.2174/138945010791011956 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 1873-5592 |
ExternalDocumentID | 20199393 |
Genre | Journal Article Review |
GroupedDBID | CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-b492t-6e685df34df102fcaea59d15b50ef160a0024304f3e8aafc0e28baba80754c632 |
IngestDate | Tue Jul 04 17:39:46 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-b492t-6e685df34df102fcaea59d15b50ef160a0024304f3e8aafc0e28baba80754c632 |
PMID | 20199393 |
ParticipantIDs | pubmed_primary_20199393 |
PublicationCentury | 2000 |
PublicationDate | 2010-May |
PublicationDateYYYYMMDD | 2010-05-01 |
PublicationDate_xml | – month: 05 year: 2010 text: 2010-May |
PublicationDecade | 2010 |
PublicationPlace | United Arab Emirates |
PublicationPlace_xml | – name: United Arab Emirates |
PublicationTitle | Current drug targets |
PublicationTitleAlternate | Curr Drug Targets |
PublicationYear | 2010 |
Score | 2.2244704 |
SecondaryResourceType | review_article |
Snippet | Progressive cartilage degradation is considered a hallmark of osteoarthritis (OA), and as such methods to inhibit this process have been extensively... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 561 |
SubjectTerms | Aggrecans - metabolism Animals Arthritis, Experimental - drug therapy Arthritis, Experimental - genetics Arthritis, Experimental - metabolism Cartilage - metabolism Cartilage - pathology Cartilage Oligomeric Matrix Protein Collagen Type II - metabolism Drug Delivery Systems - methods Extracellular Matrix Proteins - genetics Extracellular Matrix Proteins - metabolism Glycoproteins - genetics Glycoproteins - metabolism Humans Matrilin Proteins Mice Mice, Transgenic Models, Biological Osteoarthritis - drug therapy Osteoarthritis - genetics Osteoarthritis - metabolism Protease Inhibitors - therapeutic use Species Specificity |
Title | Is cartilage matrix breakdown an appropriate therapeutic target in osteoarthritis--insights from studies of aggrecan and collagen proteolysis? |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20199393 |
Volume | 11 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwELUWeumlKuonX_KB28ptNrGzzgkhBAIEqAeQuCE7tumqbHZFglT1N1T8ZmZsZzdNS0UrraJVnNhW3os1M5l5JmQnzawohXZMJaVivMRAU6Esk1YaqYvMcS8pdHaeH13ykytxNRj87GQt3Tf6U_njj3Ul_4MqnANcsUr2H5BddAon4D_gC0dAGI7PwvjYK0s3k1tMvJmi2P73Ibi46psB33oIb65XDJ_DTBo77FRaDUP-N8Y6sMZjBn189eJGjE2qGt31OtSd1CHL0CcL3IBnjktmKIS7xTF9ehfc72VNeimCrfCTubu_ieMtzPfTCSon97QNlvs_H87qGMXem2KgI366irGJ8Fk9xiZsWE_lOGPgtPy64I46xBKd1VMEXfb-qo5eEwYYwLbiAkYZg4mDSnV592JAZj71OMNEwOgK-y7-vbWntN02rZCVscRtQM6_nIU6K5zB59_HRyXpeE_PK_HWycVr8iq6FXQvcGSNDGz1hjwc13TBDxr4QRf8oAp-S37QDj9owItOKvoUPyjyg0Z-0JmjLT-gW0NbftAOP3bfksvDg4v9Ixb332CaF2nDcptLYVzGjQMz1JXKKlGYkdAisW6UJ8rLWSbcZVYq5crEplIrrVDfmpd5lr4jq9Wssh8IlcWoTKQWzoKLYI0qRKp46mRqMqtFoT6S9-HxXc-DyMp1-2DXn2zZIC-XnNskLxy81XYLTMRGb3vsHgG7_2-x |
link.rule.ids | 780 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Is+cartilage+matrix+breakdown+an+appropriate+therapeutic+target+in+osteoarthritis--insights+from+studies+of+aggrecan+and+collagen+proteolysis%3F&rft.jtitle=Current+drug+targets&rft.au=Little%2C+Christopher+B&rft.au=Fosang%2C+Amanda+J&rft.date=2010-05-01&rft.eissn=1873-5592&rft.volume=11&rft.issue=5&rft.spage=561&rft_id=info:doi/10.2174%2F138945010791011956&rft_id=info%3Apmid%2F20199393&rft_id=info%3Apmid%2F20199393&rft.externalDocID=20199393 |